murf 1

MuRF1-IN-2（实施例3），这种化合物是MuRF1抑制剂，主要应用于肌肉消耗状况、骨骼肌或心肌萎缩的研究。

MuRF1-IN-1 是MuRF1抑制剂，能减少心脏恶病质中的骨骼肌萎缩和功能障碍。

MurF-IN-1 (Compound 7)，一种MurF抑制剂，展现了针对S. pneumoniae MurF的显著抑制活性，其pIC50值为5.19。

Smurf1 inhibitor 1 is a inhibitor that promotes bone formation.

Smurf1 ligand 1 屬於 PROTAC靶蛋白配体（Ligands for Target Protein for PROTACs）, 可用於合成。

SMURF1-IN-1是一种口服活性的特异性E3泛素蛋白连接酶1（SMURF1）选择性抑制剂，IC50值为92 nM。在大鼠肺部高压模型中显示出显著疗效，适用于肺动脉高压疾病的研究。

Smurf1-IN-A01 (A01) 是泛素连接酶 Smad 泛素化调节因子-1(Smurf1)抑制剂，其kd=3.664 nM。它能够抑制 Smurf1 介导的 Smad1 5 降解，并提高 BMP-2 的反应性。

Smurf-1 modulator CMP Example 20 (Smurf-1-IN-20) 是一种有效的 Smurf-1 调节剂。

AC430 is a potent and specific small molecule inhibitor of janus kinase 2 (JAK2), which has been implicated as a target for therapy in both oncology and autoimmune disease. AC430 is currently being developed by Ambit. In preclinical studies, AC430 has exhibited potency against JAK2 and V617F mutated JAK2 in cell-based models that is at least equivalent to, and in most cases superior to, competing JAK2 inhibitors. In preclinical oncology and autoimmune models, AC430 is well tolerated and has significant efficacy at oral doses as low as 10 mg kg day.